TRCT
RXL icon

Tower Research Capital (TRC)’s ProShares Ultra Health Care RXL Stock Holding History

Tower Research Capital (TRC)’s Portfolio RXL Stock Details RXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,688
Closed -$451K – 6300
2022
Q3 		$451K Buy
11,688
+1,738
+17% +$76.6K 0.01% 1235
2022
Q2 		$434K Buy
9,950
+6,478
+187% +$298K 0.01% 1232
2022
Q1 		$178K Buy
3,472
+352
+11% +$17K ﹤0.01% 1818
2021
Q4 		$175K Sell
3,120
-2,590
-45% -$131K ﹤0.01% 1870
2021
Q3 		$271K Buy
5,710
+1,484
+35% +$75.6K 0.01% 1518
2021
Q2 		$197K Sell
4,226
-3,152
-43% -$138K 0.01% 1940
2021
Q1 		$294K Sell
7,378
-6,666
-47% -$263K ﹤0.01% 1679
2020
Q4 		$531K Sell
14,044
-3,528
-20% -$123K 0.02% 948
2020
Q3 		$574K Sell
17,572
-1,500
-8% -$48.2K 0.01% 1534
2020
Q2 		$560K Sell
19,072
-17,368
-48% -$490K 0.02% 919
2020
Q1 		$826K Buy
36,440
+26,528
+268% +$763K 0.05% 281
2019
Q4 		$315K Sell
9,912
-5,148
-34% -$144K 0.03% 429
2019
Q3 		$370K Sell
15,060
-31,384
-68% -$798K 0.03% 701
2019
Q2 		$1.22M Sell
46,444
-1,440
-3% -$35.7K 0.08% 213
2019
Q1 		$1.25M Buy
47,884
+8,108
+20% +$204K 0.08% 210
2018
Q4 		$904K Buy
39,776
+33,780
+563% +$867K 0.07% 291
2018
Q3 		$174K Buy
+5,996
New +$158K 0.01% 1046
2017
Q2 		– Sell
-2,616
Closed -$46K – 3344
2017
Q1 		$46K Buy
+2,616
New +$44K ﹤0.01% 778
2016
Q2 		– Sell
-536
Closed -$8K – 4895
2016
Q1 		$8K Sell
536
-34,204
-98% -$477K ﹤0.01% 2233
2015
Q4 		$573K Buy
34,740
+20,284
+140% +$325K 0.09% 109
2015
Q3 		$206K Buy
14,456
+13,956
+2,791% +$248K 0.02% 282
2015
Q2 		$9K Buy
500
+220
+79% +$4.01K ﹤0.01% 2818
2015
Q1 		$5K Sell
280
-2,120
-88% -$35.7K ﹤0.01% 3266
2014
Q4 		$37K Buy
+2,400
New +$35.4K ﹤0.01% 1211
2014
Q2 		– Sell
-4,000
Closed -$45K – 4561
2014
Q1 		$45K Buy
+4,000
New +$44.2K 0.01% 1172

Other funds holding RXL

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PFA
Plotkin Financial Advisors Chevy Chase, Maryland $199M AUM 19.26% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
BCWM
Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return
BC
Bartlett & Co Cincinnati, Ohio $6.16B AUM 20.29% 1-Year Est. Return

Tower Research Capital (TRC)'s RXL Position: Q4 2022 in Review

Tower Research Capital (TRC) sold out of ProShares Ultra Health Care (RXL) in Q4 2022, closing a stake of 11,688 shares — an estimated $451K sold.

Tower Research Capital (TRC) first reported a position in RXL in Q1 2014 and held it in 25 quarters. The position peaked at $1.25M in Q1 2019. 19 funds tracked by Wall St. Rank hold RXL as of Q4 2022.

  • Tower Research Capital (TRC) reported no remaining ProShares Ultra Health Care position as of Q4 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 11,688 ProShares Ultra Health Care shares in Q4 2022, an estimated $451K.
  • Tower Research Capital (TRC) first reported a position in ProShares Ultra Health Care in Q1 2014 and held it in 25 quarters.
  • Tower Research Capital (TRC)'s ProShares Ultra Health Care position peaked at $1.25M in Q1 2019.
  • 19 funds tracked by Wall St. Rank held ProShares Ultra Health Care as of Q4 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2022, filed 10 Feb 2023.